Purpose
=======

To determine whether APRV can safely enhance hemodynamics in patients with ALI/ARDS.

Methods
=======

Patients with ALI/ARDS were ventilated in pressure control (PCV) with both upper and lower inflection points eliminated from the hysteresis curve; all patients had a pulmonary artery catheter. Ventilator settings achieved a pCO~2~ of 35--45 torr and a pO~2~ of \> 60 torr. Patients were then changed to APRV. Data included: age, diagnosis, ventilator settings, hemodynamic profiles, ABG, lactate, and medications. Data (means ± SD) were compared using a Student\'s *t*-test; significance assumed for *P* \< 0.05.

Results
=======

Mean age was 58 ± 9 years (*n* = 12) and mean Lung Injury Score was 7.6 ± 2.1. Temperature (PCV 100.8 + 1 v APRV 100.6 + 1F; *P* \> 0.5) and PaO~2~/FIO~2~ (PCV 168 ± 24 v APRV 182 ± 18; *P* \> 0.0.5) were similar. Diagnoses were pneumonia (22%), abdominal sepsis (45%), trauma (33%), bacteremia (18%) and transfusion related lung injury (1%). Peak airway pressures fell from 38 ± 3 (PCV) 25± 3 cmH~2~O(APRV, *P* \< 0.05); mean pressures fell from 18 ± 3 (PCV) to 12 ± 2 cmH~2~O (APRV; *P* \< 0.05). Paralytic use (PCV 74% v APRV 4%; *P* \< 0.05) and sedative use significantly declined (PCV 100% v. APRV 68%, *P* \< 0.05). Pressor use decreased substantially (PCV 92% v ARPV 45%, *P* \< 0.05). Lactate levels remained unchanged (PCV 2.2 ± 0.6 v APRV 1.8 ± 0.8 mmol/l; *P* \> 0.05). Cardiac index rose from 3.2 ± 0.4 (PCV) to 4.6 ± 0.3 l/min/m^2^ BSA (APRV; *P* \< 0.05) while DO~2~I increased by 36% (*P* \< 0.05). CVP declined from 18± 4 (PCV) to 12± 5 cmH~2~O (APRV; *P* \> 0.05).

Conclusion
==========

APRV may be used safely in patients with ALI/ARDS and decreases the need for paralysis and sedation compared to PCV. APRV increases cardiac performance with decreased pressor use and CVP in patients with ALI/ARDS. Further study of ARPV is warranted to discover its impact on resource utilization and patient outcome.
